In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of TG Therapeutics Inc (NASDAQ:TGTX) with a $28 price target, after the company announced that a Special Protocol Assessment has been approved by the FDA for the first Phase 3 trial of its proprietary combination of TG-1101 and TGR-1202 (referred to as TG-1303) for the treatment of CLL.

Aschoff wrote, “TG will enroll its first patient for the UNITY-CLL trial imminently, and we believe that TG-1303 will prove safe and effective in front-line and relapsed/refractory CLL. Exactly how TG was going to design a trial to more expeditiously develop TG-1303 was an unknown until today, and the clarity afforded by the SPA is a major positive, in our view.”

Furthermore, “We look forward to ASH 2015, as the next major clinical data catalyst for TG, particularly with its non-chemotherapy tripledrug combination TG-1303 plus ibrutinib), and to the imminent start of new triple-regimen trials, particularly with TG-1101, TGR-1202 and a PD-1 inhibitor, as well as with potential quad combination therapy. We are also expecting Phase 3 GENUINE trial data in 2H16, and the company’s expansion into autoimmune disease, particularly MS.”

Bottom line: “We maintain our confidence in TG’s continued rapid progress through the clinic and emphasize the importance of owning assets that if approved, should allow the company to afford patients a combination therapy at a very competitive price vs. the purchase of both activities from two different sources, which is important to payers given the extended duration of lymphoma treatment vs. other more aggressive cancers.”

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jonathan Aschoff has a total average return of 7.4% and a 47.6% success rate. Aschoff has a -12.6% average return when recommending TGTX, and is ranked #388 out of 3765 analysts.

TGTX Chart